The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia
Information source: Hamamatsu University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Eosinophilic Pneumonia; Chronic Disease
Intervention: prednisolone 0.5 mg/kg/day for three months (Drug); prednisolone 0.5 mg/kg/day for six months (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Hamamatsu University Official(s) and/or principal investigator(s):
Kingo Chida, MD, PhD, Study Chair, Affiliation: Hamamatsu University
Summary
A comparison of 3 months-prednisolone administration with 6 months-prednisolone therapy in
the treatment of chronic eosinophilic pneumonia. Three months-prednisolone administration
may be as effective as 6 months-therapy.
Clinical Details
Official title: Phase 4, Randomized Study of Three Months-prednisolone Therapy in the Treatment of Chronic Eosinophilic Pneumonia
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Efficacy of 3 versus 6 months-prednisolone therapy for chronic eosinophilic pneumonia
Secondary outcome: Safety of 3 versus 6 months-prednisolone therapy for chronic eosinophilic pneumonia
Eligibility
Minimum age: 16 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Biopsy-proven chronic eosinophilic pneumonia
Exclusion Criteria:
- Patients who received oral glucocorticosteroid (more than 10 mg)
- Immunosuppressive drug
Locations and Contacts
Hamamatsu University School of Medicine, Hamamatsu, Japan
Additional Information
Starting date: June 2008
Last updated: September 18, 2014
|
